Aditya Kumar Halwasiya, Chairman and Managing Director of Cupid Ltd., has further increased his personal stake in the company. Through an open market transaction on Monday, Halwasiya acquired an additional 1,100,000 shares, representing 0.08 percent of Cupid's total equity. This latest purchase raises his individual shareholding to 33.53 percent.
This acquisition marks Halwasiya's third disclosed purchase of Cupid shares within the last fortnight. Previously, he acquired 803,000 shares and 1,395,538 shares in two separate open market transactions. Cumulatively, these three transactions bring his total share acquisition to 3,298,538 Cupid shares in a short span.
The company recently reported a robust financial performance for the first quarter of fiscal year 2027 (Q1 FY27). Net profit surged by 194 percent year-on-year to Rs 44.15 crore, up from Rs 15.01 crore in Q1 FY26. Total income also saw a significant jump of 142 percent year-on-year, reaching Rs 156.98 crore from Rs 59.80 crore in the prior-year quarter. EBITDA climbed 265 percent to Rs 60.06 crore, with the EBITDA margin improving to 39 percent.
Commenting on the Q1 earnings, Halwasiya stated, "We have commenced FY27 with strong momentum across both our international B2B healthcare and Consumer Healthcare & FMCG businesses. Healthy execution during the quarter, improving order visibility and sustained demand across our core segments have strengthened our confidence in the Company's growth trajectory." He added that supported by a robust order book, the company has enhanced its FY27 guidance to Rs 725-750 crore in revenue and Rs 210-225 crore in Net Profit.
On the stock market, Cupid shares closed up 0.53 percent at Rs 286.10 on Monday. The stock has demonstrated significant growth, gaining 243.13 percent over the past six months. Investors should note that Cupid's securities are currently under the long-term Additional Surveillance Measure (ASM) framework on both the BSE and NSE, a measure exchanges implement to alert investors about high volatility.
Cupid Ltd. specializes in the manufacturing and marketing of male and female condoms, water-based personal lubricants, and in-vitro diagnostic (IVD) kits. The company also maintains a diverse portfolio within the Consumer Healthcare and FMCG sectors.